Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer
暂无分享,去创建一个
Christine B. Peterson | K. Do | K. Garey | R. Jenq | C. Peterson | P. Okhuysen | E. Obi | S. Aitken | J. Adachi | R. Dillon | Ying Jiang | Liangliang Zhang | A. Olvera | D. Francisco | Eduardo Yepez Guevara
[1] E. Kuijper,et al. Plasmid-mediated metronidazole resistance in Clostridioides difficile , 2019, Nature Communications.
[2] L. Munoz-Price,et al. Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] H. Dupont,et al. Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule , 2019, mSystems.
[4] Soo‐Ki Kim,et al. Probiotic supplements might not be universally-effective and safe: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] D. Gerding,et al. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection with Greater Severity and Higher Recurrence Rates. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] H. Fan,et al. Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation , 2018, Front. Microbiol..
[7] B. Helmink,et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.
[8] F. Qeadan,et al. Zolpidem Use Is a Potential Risk Factor for Clostridium difficile Colitis in Hospitalized Patients: A Large Case Control Study , 2018, American Journal of Gastroenterology.
[9] David H. Chong,et al. Rapid gastrointestinal loss of Clostridial Clusters IV and XIVa in the ICU associates with an expansion of gut pathogens , 2018, PloS one.
[10] K. Carroll,et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] L. Perez,et al. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment , 2017, Medical mycology case reports.
[12] R. Madan,et al. Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection. , 2017, Anaerobe.
[13] F. Månsson,et al. The Association between GABA-Modulators and Clostridium difficile Infection – A Matched Retrospective Case-Control Study , 2017, PloS one.
[14] Jennifer Beardsley,et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. , 2017, The Cochrane database of systematic reviews.
[15] L. Dembry,et al. Epidemiology of Clostridium difficile infection in hospitalized oncology patients. , 2016, American journal of infection control.
[16] Ben Nichols,et al. Distributed under Creative Commons Cc-by 4.0 Vsearch: a Versatile Open Source Tool for Metagenomics , 2022 .
[17] Peter T. McKenney,et al. Clostridium difficile colitis: pathogenesis and host defence , 2016, Nature Reviews Microbiology.
[18] K. Garey,et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. , 2016, The Journal of hospital infection.
[19] A. Wanger,et al. Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption , 2016, Infection.
[20] Dustin L. Stwalley,et al. The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases , 2016, BMC Infectious Diseases.
[21] V. Young,et al. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine , 2016, mSphere.
[22] L. Rybicki,et al. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients , 2016, Bone Marrow Transplantation.
[23] V. Young,et al. Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. , 2015, Annual review of microbiology.
[24] L. Kitanovski,et al. Bifidobacterium breve Sepsis in Child with High-Risk Acute Lymphoblastic Leukemia , 2015, Emerging infectious diseases.
[25] A. Levy,et al. Incidence and Costs of Clostridium difficile Infections in Canada , 2015, Open forum infectious diseases.
[26] S. Rodríguez,et al. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] K. Garey,et al. Healthcare Resource Utilization for Recurrent Clostridium difficile Infection in a Large University Hospital in Houston, Texas , 2014, PloS one.
[28] R. Britton,et al. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. , 2014, Gastroenterology.
[29] Yeul-Hong Kim,et al. Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy , 2014, Supportive Care in Cancer.
[30] V. Mai,et al. Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.
[31] Susan Holmes,et al. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data , 2013, PloS one.
[32] David N. Fisman,et al. Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection , 2013, Antimicrobial Agents and Chemotherapy.
[33] Areej Khan,et al. The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. , 2012, Recent patents on anti-infective drug discovery.
[34] E. Pamer,et al. Critical Role for MyD88-Mediated Neutrophil Recruitment during Clostridium difficile Colitis , 2012, Infection and Immunity.
[35] William A. Walters,et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms , 2012, The ISME Journal.
[36] D. Slymen,et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] William A. Walters,et al. QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.
[38] Martin Hartmann,et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.
[39] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[40] E. Kuijper,et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. , 2008, The Journal of antimicrobial chemotherapy.
[41] R. Knight,et al. Quantitative and Qualitative β Diversity Measures Lead to Different Insights into Factors That Structure Microbial Communities , 2007, Applied and Environmental Microbiology.
[42] S. Routhier,et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] R. Knight,et al. UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.
[44] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[45] G. Macfarlane,et al. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. , 2002, Journal of medical microbiology.
[46] T. Sauerbruch,et al. Clostridium difficile infection in patients with neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] D. Gerding,et al. Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] A. Glatt,et al. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] S. Hirschman,et al. Clostridium difficile diarrhea induced by cancer chemotherapy. , 1992, Archives of internal medicine.
[50] R. Warren,et al. ATYPICAL CLOSTRIDIUM DIFFICILE COLITIS IN NEUTROPENIC PATIENTS , 1982, The Lancet.